[{"NetIncomeLoss_1_Q2_USD":25315000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"EquitySecuritiesFvNiGainLoss_1_Q2_USD":95200000.0,"EquitySecuritiesFvNiGainLoss_2_Q2_USD":102868000.0,"AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_0_Q2_USD":-266000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":71887000.0,"RestrictedCashCurrent_0_Q2_USD":847000.0,"InventoryFinishedGoods_0_Q2_USD":3384000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1284000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-181264000.0,"AssetsCurrent_0_Q2_USD":906039000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-34000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":89768000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":42252000.0,"PaymentsToAcquireAvailableForSaleSecurities_2_Q2_USD":456331000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":8708137.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":5214988.0,"AvailableForSaleSecurities_0_Q2_USD":788848000.0,"CommonStockSharesIssued_0_Q2_shares":60413756.0,"IncreaseDecreaseInAccountsReceivableRelatedParties_2_Q2_USD":8473000.0,"Assets_0_Q2_USD":1314041000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":1431000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":2829000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":37067000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":6136000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"AvailableForSaleSecuritiesAmortizedCost_0_Q2_USD":787298000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":61709000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":2740000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":15858000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":80709000.0,"EarningsPerShareBasic_2_Q2_USD":-1.59,"EarningsPerShareBasic_1_Q2_USD":0.42,"ProceedsFromSaleOfAvailableForSaleSecurities_2_Q2_USD":28850000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":273996000.0,"FinanceLeasePrincipalPayments_2_Q2_USD":91000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":58996278.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":61146231.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-239000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":217000.0,"AccountsReceivableNetCurrent_0_Q2_USD":14893000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":824000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":415000.0,"CommonStockValue_0_Q2_USD":60000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":6036000.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-25000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":12000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":91426000.0,"IncreaseDecreaseInInventories_2_Q2_USD":-521000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-92279000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":28144000.0,"OtherAssetsNoncurrent_0_Q2_USD":2627000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":335639000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":36308000.0,"Liabilities_0_Q2_USD":618454000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":1391000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":193670000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":98018000.0,"OperatingIncomeLoss_1_Q2_USD":-63055000.0,"Goodwill_0_Q2_USD":44406000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-92886000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":25730000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":22428000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":42585000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-7801000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":58996278.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":59995617.0,"InventoryWorkInProcess_0_Q2_USD":7677000.0,"LiabilitiesCurrent_0_Q2_USD":219729000.0,"AccountsPayableCurrent_0_Q2_USD":9014000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":58196000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-198000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":14332000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":131275000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_2_Q2_USD":40000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q2_USD":89000.0,"AdditionalPaidInCapital_0_Q2_USD":2220963000.0,"AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0_Q2_USD":1550000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":338407000.0,"DeferredIncomeTaxLiabilitiesNet_0_Q2_USD":33306000.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_1_Q2_USD":0.0,"AvailableForSaleSecuritiesGrossRealizedGainLossNet_2_Q2_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":48339000.0,"NetIncomeLoss_2_Q2_USD":-93710000.0,"InvestmentsFairValueDisclosure_0_Q2_USD":929068000.0,"OperatingIncomeLoss_2_Q2_USD":-183720000.0,"PaymentsToAcquireEquityMethodInvestments_2_Q2_USD":9600000.0,"EarningsPerShareDiluted_1_Q2_USD":0.41,"InventoryNet_0_Q2_USD":11061000.0,"InvestmentIncomeInterest_2_Q2_USD":4716000.0,"InvestmentIncomeInterest_1_Q2_USD":1797000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":1562000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":134898000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1314041000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":35836000.0,"PreferredStockSharesAuthorized_0_Q2_shares":25000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":42581000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":22409000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":7258000.0,"OperatingExpenses_2_Q2_USD":281738000.0,"OperatingExpenses_1_Q2_USD":124764000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":3462000.0,"ProfitLoss_2_Q2_USD":-93710000.0,"StockholdersEquity_0_Q2_USD":695587000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":18179000.0,"LongTermInvestments_0_Q2_USD":4068000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":149000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1526720000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-97837000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":-17955000.0,"CommonStockSharesOutstanding_0_Q2_shares":60413756.0,"EarningsPerShareDiluted_2_Q2_USD":-1.59,"RestrictedCashNoncurrent_0_Q2_USD":1921000.0,"ShortTermInvestments_0_Q2_USD":477777000.0,"Ticker":"RARE","CIK":"1515673","name":"ULTRAGENYX PHARMACEUTICAL INC.","OfficialName":"Ultragenyx Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5418950849.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200731"}]